60. 再生不良性貧血 Aplastic anemia Clinical trials / Disease details
臨床試験数 : 235 / 薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04409080 (ClinicalTrials.gov) | January 13, 2021 | 26/5/2020 | REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | A Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | Severe Aplastic Anemia (SAA) | Drug: REGN7257 | Regeneron Pharmaceuticals | NULL | Recruiting | 18 Years | N/A | All | 48 | Phase 1/Phase 2 | United States;France;Korea, Republic of;United Kingdom |
| 2 | EUCTR2020-002031-29-FR (EUCTR) | 21/12/2020 | 10/07/2020 | REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY | SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;United Kingdom;Korea, Republic of | ||
| 3 | EUCTR2020-002031-29-GB (EUCTR) | 05/11/2020 | 30/06/2020 | REGN7257 in Adult Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy | A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE THERAPY | SEVERE APLASTIC ANEMIA MedDRA version: 20.0;Level: LLT;Classification code 10002274;Term: Anemia aplastic;System Organ Class: 100000004851;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Product Code: REGN7257 INN or Proposed INN: Not Applicable Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (IL2-RG) ANTIBODY | Regeneron Pharmaceuticals, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 1;Phase 2 | United States;France;United Kingdom;Korea, Republic of |